<DOC>
<DOCNO>EP-0648212</DOCNO> 
<TEXT>
<INVENTION-TITLE>
BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS PHARMACEUTICAL
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P300	C07D27700	A61P900	A61K314402	A61P900	A61K31422	A61P306	A61K3141	A61K31505	C07D21300	A61K31505	A61K3144	C07D41312	A61K3142	C07D26300	A61K3144	C07D23900	C07D26358	A61K314402	A61K31423	A61K31496	C07D23942	A61K3141	A61K31423	A61K31496	A61K31422	A61K3142	C07D21374	A61P310	C07D41300	A61P912	C07D27738	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C07D	A61P	A61K	A61P	A61K	A61P	A61K	A61K	C07D	A61K	A61K	C07D	A61K	C07D	A61K	C07D	C07D	A61K	A61K	A61K	C07D	A61K	A61K	A61K	A61K	A61K	C07D	A61P	C07D	A61P	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P3	C07D277	A61P9	A61K31	A61P9	A61K31	A61P3	A61K31	A61K31	C07D213	A61K31	A61K31	C07D413	A61K31	C07D263	A61K31	C07D239	C07D263	A61K31	A61K31	A61K31	C07D239	A61K31	A61K31	A61K31	A61K31	A61K31	C07D213	A61P3	C07D413	A61P9	C07D277	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
A compound of formula (I): A
<
1
>
-X-(CH2)n-O-A
<
2
>
-A
<
3
>
-Y.R
<
2
>
 or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A
<
1
>
 represents a substituted or unsubstituted aromatic heterocyclyl group; A
<
2
>
 represents a benzene ring having three optional substituents; A
<
3
>
 represents a moiety of formula -(CH2)m-CH(OR
<
1
>
)-wherein R
<
1
>
 represents substituted or unsubstituted alkyl, aryl, aralkyl or alkylcarbonyl and m represents an integer in the range of from 1 to 5, or A
<
3
>
 represents a moiety of formula -(CH2)m-1-CH=C(OR
<
1
>
)- wherein R
<
1
>
 and m are as defined above; R
<
2
>
 represents OR
<
3
>
 wherein R
<
3
>
 represents hydrogen, alkyl, aryl or aralkyl or R
<
2
>
 represents an aromatic heterocyclyl group or -NR
<
4
>
R
<
5
>
 wherein R
<
4
>
 and R
<
5
>
 each independently represent hydrogen, alkyl or alkylcarbonyl or R
<
4
>
 and R
<
5
>
 together with the nitrogen atom to which they are attached form a heterocyclic ring, providing that R
<
2
>
 represents an aromatic heterocyclyl group only when Y as defined below represents a bond; X represents NR wherein R represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; Y represents CO or CS or a bond providing that Y represents a bond only when R
<
2
>
 represents the above-mentioned aromatic heterocyclyl group; and n represents an integer in the range of from 2 to 6; a process for preparing such a compound, a composition comprising such a compound and the use of such a compound and composition in medicine.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
This invention relates to certain novel compounds, to a process for preparing such
compounds, to pharmaceutical compositions containing such compounds and to the
use of such compounds and compositions in medicine.European Patent Applications, Publication Numbers 0008203, 0139421,
0155845, 0177353, 0193256, 0207581, 0208420, 0306228 and International Patent
Application Publication No. WO 9101337 relate to thiazolidinedione derivatives
which are disclosed as having hypoglycaemic and hypolipidaemic activity. Chem.
Pharm. Bull 1982, 30 (10) 3580-3600 relates to certain thiazolidinedione derivatives
having hypoglycaemic and hypolipidaemic activities.International Patent Application, Publication Number WO 91/19702 discloses
compounds of formula (A) and (B):

and

wherein A is

or
n is 0 or 1;m is 0, 1 or 2;---- represents a bond or no bond; R is (C1-C8)alkyl, (C3-C7)cycloalkyl, (C3-C8)alkenyl, (C3-C8)alkynyl,
phenyl, (C7-C8)phenylalkyl, (C2-C8)alkanoyl, or one of said groups mono- or
disubstituted with (C1-C3)alkyl, trifluoromomethyl, hydroxy, (C1-C3)alkoxy, fluoro
or chloro;W is O, CO, CH2, CHOH or -CH=CH-;X is S, O, NR2, -CH=CH-, -CH=N- or -N=CH-'R2 is hydrogen, (C1-C3)alkyl, phenyl or benzyl;Y is CH or N;Z is H, amino, (C1-C7)alkyl, (C3-C7)cycloalkyl, phenyl, or phenyl mono- or
disubstituted with (C1-C3)alkyl, trifluoromethyl, (C1-C3)alkoxy, phenyl, phenoxy,
benzyl, benzyloxy, fluoro or chloro;Z1 is hydrogen or (C1-C3)alkyl;X1 is O, S, SO or SO2; andY1 is hydroxy, (C1-C3)alkoxy, phenoxy, benzyloxy, amino,
(C 1-C4)alkanoylamino, (C1-C4)alkanesulfonyl-amino, benzenesulfonylamino,
naphthalenesulfonylamino, di[(C1-C3)alkyl]aminosulfonylamino, or one of said
groups mono- or disubstituted with (C1-C3)alkyl, trifluoromethyl, hydroxy,
(C1-C3)alkoxy, fluoro or chloro; the pharmaceutically-acceptable cationic salts
thereof when Y1 is hydroxy; and the pharmaceutically-acceptable acid addition salts
thereof when the compounds contain a basic nitrogen atom.The compounds of formula (A) are stated to be useful as hypoglycaemic and
hypochlolesterolemic agentsInternational Patent Application, Publication Number WO 92/02520 discloses
certain oxazolidinedione derivatives which are stated to be useful in the treatment of
inter alia Type II diabetes.It has now surprisingly been discovered that certain novel compounds,
structurally distinct from the abovementioned compounds, show particularly good
blood-glucose lowering activity and are therefore of potential use in the treatment
and/or prophylaxis of hyperglycaemia and are of
</DESCRIPTION>
<CLAIMS>
A compound of formula (I):

A
1
―X―(CH
2
)
2
―O―A
2
―A
3
―YR
2

or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof,
and/or a pharmaceutically acceptable solvate thereof, wherein:


A
1
 represents a moiety of formula (a):


wherein X
1
 represents oxygen or sulphur;
A
2
 represents a moiety of formula (e):


wherein R
10
 and R
11
 each independently represent hydrogen, halogen, C
1-6
-alkyl
or C
1-6
-alkoxy;
A
3
 represents a moiety of formula -CH
2
-CH(OR
1
)- wherein R
1
 represents
unsubstituted ethyl or ethyl substituted with halo, hydroxy, C
1-6
-alkoxy or a
moiety -NR
s
R
t
, wherein R
s
 and R
t
 each independently represents hydrogen or
C
1-6
-alkyl or R
s
 and R
t
 together with the nitrogen atom to which they are
attached form a 5- or 6- membered heterocyclic ring selected from N-pyrrolidinyl,

N-piperidinyl and N-morpholinyl; or R
1
 is substituted or
unsubstituted phenyl C
1-6
-alkyl wherein substituents on the phenyl ring are
selected from chloro, methyl and methoxy and substituents on the C
1-6
-alkyl
group are selected from the list consisting of halo, hydroxy, C
1-6
-alkoxy or a
moiety -NR
s
R
t
, wherein R
s
 and R
t
 each independently represents hydrogen or 
C
1-6
-alkyl or R
s
 and R
t
 together with the nitrogen atom to which they are
attached form a 5- or 6- membered heterocyclic ring selected from N-pyrrolidinyl,

N-piperidinyl and N-morpholinyl;
R
2
 represents OR
3
 wherein R
3
 represents hydrogen or C
1-6
-alkyl;
X represents NR wherein R represents a hydrogen atom or a C
1-6
-alkyl group;
and
Y represents CO or CS.
A compound according to claim 1, wherein R
1
 represents benzyl.
A compound according to claim 1, wherein R
1
 represents substituted ethyl
and the substituent is attached to the terminal carbon atom of the ethyl group.
A compound according to claim 1 or claim 3, wherein R
1
 is trifluoroethyl.
A compound according to claim 1 to selected from the list consisting of:


methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-ethoxypropanoate;
methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-propoxypropanoate;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl-2-propoxypropanoic
acid;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-propoxypropanoic

acid, sodium salt;
methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(phenylmethoxy)propanoate;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(phenylmethoxy)propanoic

acid;
3-[4-[2- [N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(phenylmethoxy)propanoic

acid, sodium salt; 
methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(2,2,2-trifluoroethoxy)propanoate;
ethyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-ethoxypropanoate;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-ethoxypropanoic

acid;
ethyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
-2-methoxyphenyl]-2-ethoxypropanoate;
methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(2-phenylethoxy)propanoate;
3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(2-phenylethoxy)propanoic

acid; and
methyl 3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]
phenyl]-2-(2-methoxyethoxy)propanoate;

or a tautomeric form thereof, and/or a
pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable

hydrate thereof.
An enantiomerically enriched compound of formula (I) wherein Y
represents CO and A
1
, A
2
, A
3
, R
1
, R
2
, R
3
 and X are as defined in relation to
formula (I) according to claim 1, or a tautomeric form thereof and/or a

pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable
solvate thereof.
A compound according to claim 6, or a tautomeric form thereof and/or a
pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable

solvate thereof, in optically pure form.
A pharmaceutical composition comprising a compound of formula (I)
according to claim 1, or a tautomeric form thereof, or a pharmaceutically

acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a
pharmaceutically acceptable carrier therefor. 
A compound of formula (I) according to claim 1, or tautomeric form
thereof and/or a pharmaceutically acceptable salt thereof and/or a

pharmaceutically acceptable solvate thereof, for use as an active therapeutic
substance.
A compound of formula (I) according to claim 1, or a tautomeric form
thereof and/or a pharmaceutically acceptable salt thereof and/or a

pharmaceutically acceptable solvate thereof, for use in the treatment of and/or
prophylaxis of hyperglycaemia.
A compound of formula (I) according to claim 1, or a tautomeric form
thereof and/or a pharmaceutically acceptable salt thereof and/or a

pharmaceutically acceptable solvate thereof, for use in the treatment and/or
prophylaxis of hyperlipidaemia, hypertension, cardiovascular disease and the

regulation of appetite and food intake in subjects suffering from disorders
associated with under-eating and disorders associated with over-eating.
The use of a compound of formula (I) according to claim 1, or a
tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a

pharmaceutically acceptable solvate thereof, for the manufacture of a medicament
for the treatment and/or prophylaxis of hyperglycaemia.
The use of a compound of formula (I) according to claim 1, or a
tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or

a pharmaceutically acceptable solvate thereof, for the manufacture of a
medicament for the treatment and/or prophylaxis of hyperlipidaemia,

hypertension, cardiovascular disease and the regulation of appetite and food intake
in subjects suffering from disorders associated with under-eating and disorders

associated with over-eating.
</CLAIMS>
</TEXT>
</DOC>
